Hong Kong Stock Alert | HEARTCARE-B (06609) Surges Over 10% Before Earnings as Company Expects First Half Turnaround with Profit Exceeding RMB 40 Million

Stock News
08/29

HEARTCARE-B (06609) climbed more than 10%, and as of the time of writing, the stock was up 10.3% to HK$56.75 with a trading volume of HK$13.4465 million.

On the news front, HEARTCARE-B will hold a board meeting today to review and approve the interim results of the company and its subsidiaries for the six months ended June 30, 2025, among other matters.

The company previously announced that it expects to achieve a net profit attributable to shareholders of no less than RMB 40 million for the first half of 2025. The turnaround from loss to profit is primarily attributed to revenue growth driven by increased sales of newly launched hemorrhagic stroke treatment devices, as well as acute ischemic stroke treatment devices and other hemorrhagic stroke treatment devices. Additionally, effective cost control measures for sales costs and administrative expenses have reduced the group's overall expense ratio, while changes in the development stages of the group's R&D projects have led to decreased research and development expenditures. Fair value gains on financial assets measured at fair value through profit or loss have also increased.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10